GNH USA

Europe — EMA

Lazcluze (Lazertinib Mesilate Monohydrate)

GNH USA supplies Lazcluze (Lazertinib), a tyrosine kinase inhibitor for EGFR‑mutated non‑small cell lung cancer. Request a quote for global supply.

Lazertinib Mesilate Monohydrate

Request sourcing

1
Pack/s

What is Lazertinib Mesilate Monohydrate?

Lazertinib, the active ingredient in Lazcluze, is a tyrosine kinase inhibitor presented as a unknown/unknown for oral use. It treats non‑small cell lung cancer that carries epidermal growth factor receptor (EGFR) mutations in adult patients.

GNH USA supplies Lazcluze as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

What is Lazertinib Mesilate Monohydrate used for?

Lazcluze is a targeted therapy that acts on EGFR‑mutated non‑small cell lung cancer.

Non‑small cell lung cancer with EGFR mutations: improves progression‑free survival and tumor response in patients whose tumours harbor activating EGFR alterations.

What are the side effects of Lazertinib Mesilate Monohydrate?

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Diarrhea: mild to moderate gastrointestinal upset. - Skin rash: papulopustular eruption, often on the face or trunk. - Nausea: occasional feeling of queasiness. - Decreased appetite: reduced food intake. - Fatigue: general tiredness. - Elevated liver enzymes: transient increase in ALT/AST.

Serious or Rare Side Effects: - Interstitial lung disease: new or worsening respiratory symptoms. - Severe hepatic injury: marked elevation of liver enzymes or jaundice. - QT interval prolongation: potential cardiac arrhythmia risk. - Stevens‑Johnson syndrome: severe skin and mucosal reactions. - Grade 3/4 neutropenia: significant reduction in white blood cells. - Hepatotoxicity: liver failure requiring medical intervention.

What precautions apply to Lazertinib Mesilate Monohydrate?

Patients should be monitored for specific safety concerns before and during treatment.

Liver function monitoring: assess ALT, AST, and bilirubin regularly. Cardiac assessment: obtain baseline ECG and monitor QT interval. Pulmonary evaluation: watch for signs of interstitial lung disease. Avoid use in severe hepatic impairment: contraindicated in patients with Child‑Pugh C. Drug interaction awareness: review concomitant medications that affect CYP3A4. Store at below 25°C: keep in original container, protect from moisture and light.

What does Lazertinib Mesilate Monohydrate interact with?

Lazcluze may interact with other medicines that influence its metabolism or cardiac safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - QT‑prolonging agents (e.g., certain antiarrhythmics): additive risk of arrhythmia.

Moderate Interactions (Monitor Closely):\n- Antacids containing aluminum or magnesium: may affect absorption, separate dosing by at least 2 hours. - Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise drug levels. - Warfarin: monitor INR as EGFR inhibitors can alter coagulation parameters.

Frequently asked questions

What is Lazcluze used for?+
Lazcluze contains lazertinib, an EGFR‑targeted tyrosine kinase inhibitor indicated for the treatment of adult patients with non‑small cell lung cancer that harbors activating EGFR mutations. It is used when the tumour’s genetic profile matches the drug’s mechanism of action.
How does lazertinib work?+
Lazertinib binds to the ATP‑binding pocket of mutant EGFR kinase domains, blocking phosphorylation of downstream signaling proteins. This inhibition stops the proliferative and survival signals that drive cancer cell growth, leading to tumor regression in EGFR‑mutated lung cancers.
What is the usual dose of Lazcluze?+
The prescribed dose of Lazcluze is determined by the treating oncologist based on the patient’s clinical condition, renal and hepatic function, and any concomitant therapies. The prescriber sets the exact regimen and schedule.
Is Lazcluze safe during pregnancy or breastfeeding?+
Safety data for lazertinib in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy unless the potential benefit justifies the risk, and breastfeeding is not recommended while receiving the medication.
How do I order Lazcluze from GNH USA?+
To request Lazcluze, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.
How does Lazcluze compare with other EGFR inhibitors?+
Lazcluze (lazertinib) is a third‑generation EGFR inhibitor designed to target both sensitizing and resistant EGFR mutations, including T790M. Compared with first‑generation agents (e.g., erlotinib) and second‑generation agents (e.g., afatinib), lazertinib often shows improved activity against resistant mutations and a distinct safety profile.
What are the storage and handling requirements for Lazcluze?+
Lazcluze should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct light. Keep the product out of reach of children and avoid storing in humid environments such as bathrooms.
How is Lazcluze administered?+
Lazcluze is taken orally, usually as a whole tablet swallowed with water. It is typically administered once daily, preferably at the same time each day, and may be taken with or without food as directed by the prescriber.
What are the most serious risks associated with Lazcluze?+
Serious risks include interstitial lung disease, severe hepatic injury, QT interval prolongation, and rare but severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for respiratory symptoms, liver function abnormalities, and cardiac changes.
Who should not use Lazcluze?+
Lazcluze is contraindicated in patients with known hypersensitivity to lazertinib or any excipients, and in those with severe hepatic impairment (Child‑Pugh C). Caution is also advised for patients with a history of cardiac arrhythmias or uncontrolled QT prolongation.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Lazertinib Mesilate Monohydrate
Route
Oral Use
Manufacturer
Janssen-Cilag International Nv
Origin
EU

Related products

Lazcluze

Lazcluze

Lazertinib Mesilate Monohydrate

Janssen-Cilag International Nv
EU
Lazcluze

Lazcluze

Lazertinib Mesilate Monohydrate

Janssen-Cilag International Nv
EU
Lazcluze

Lazcluze

Lazertinib Mesilate Monohydrate

Janssen-Cilag International Nv
EU